Predictive Oncology Enters Material Definitive Agreement

TL;DR

Predictive Oncology (POAI) signed a big deal, filing an 8-K on May 3rd.

AI Summary

Predictive Oncology Inc. announced on May 3, 2024, that it entered into a material definitive agreement. The company, formerly known as Skyline Medical Inc., is incorporated in Delaware and headquartered in Pittsburgh, PA.

Why It Matters

This filing indicates a significant development for Predictive Oncology Inc., likely involving a new contract or partnership that could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry risks related to the terms of the agreement, potential future performance, and market reaction.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• Skyline Medical Inc. (company) — Former company name
• May 3, 2024 (date) — Date of earliest event reported
• 001-36790 (company) — SEC File Number
• 33-1007393 (company) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share POAI NASDAQ Capital Market
• $3,696,000 — fined below) relates to the offering of $3,696,000 in shares of the Company's common stock

Filing Documents

• f8k_050324.htm (8-K) — 26KB
• exh_101.htm (EX-10.1) — 224KB
• 0001171843-24-002541.txt ( ) — 481KB
• poai-20240503.xsd (EX-101.SCH) — 3KB
• poai-20240503_lab.xml (EX-101.LAB) — 33KB
• poai-20240503_pre.xml (EX-101.PRE) — 22KB
• f8k_050324_htm.xml (XML) — 4KB

01 Entry into a Material Agreement

Item 1.01 Entry into a Material Agreement On May 3, 2024, Predictive Oncology Inc., a Delaware corporation, (the "Company"), entered into an ATM Sales Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent to sell shares of the Company's common stock, par value $0.01 per share, from time to time, through an "at the market offering" program pursuant to which Wainwright will act as sales agent. The prospectus supplement to the Registration Statement (defined below) relates to the offering of $3,696,000 in shares of the Company's common stock. The issuance and sale, if any, of common stock by the Company under the Sales Agreement is subject to the effectiveness of the Company's registration statement on Form S-3 to be filed with the United States Securities and Exchange Commission (the "SEC") on May 3, 2024 (the "Registration Statement"). The Company makes no assurances as to whether the Registration Statement will become effective or, if it does become effective, as to the continued effectiveness of the Registration Statement. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Wainwright may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, and applicable Agreement for any reason or by Wainwright upon written notice

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Sales Agreement, dated as of May 3, 2024, by and between the Registrant and H.C. Wainwright & Co., LLC. 104 Cover Page Interactive Data File (embedded within the XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY INC. Date: May 3, 2024 By: /s/ Raymond Vennare Name: Raymond Vennare Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR